ArticleInternational journal of clinical and experimental pathology2017
Association between glutathione peroxidase-1 (GPX1) Rs1050450 polymorphisms and cancer risk.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Evaluation of the Variability in Selenoprotein Genes in Hepatocellular Carcinoma Patients.Biochemical genetics · 2026Article
- Oxidative stress markers and inflammation in type 1 and 2 diabetes are affected by BMI, treatment type, and complications.Scientific reports · 2025Article
- Genetic Variants in Oxidative Stress-Related Genes and Their Impact on Prognosis and Treatment Response in Chronic Myeloid Leukemia Patients.International journal of molecular sciences · 2025Article
- Analysis of damaging non-synonymous SNPs in GPx1 gene associated with the progression of diverse cancers through a comprehensive in silico approach.Scientific reports · 2024Article
- Glutathione Peroxidases: An Emerging and Promising Therapeutic Target for Pancreatic Cancer Treatment.Antioxidants (Basel, Switzerland) · 2024Review
- Genetical Signature-An Example of a Personalized Skin Aging Investigation with Possible Implementation in Clinical Practice.Journal of personalized medicine · 2023Article
- The Role of Selenium and Manganese in the Formation, Diagnosis and Treatment of Cervical, Endometrial and Ovarian Cancer.International journal of molecular sciences · 2023Review
- Polymorphisms of Antioxidant Enzymes SOD2 (rs4880) and GPX1 (rs1050450) Are Associated with Bladder Cancer Risk or Its Aggressiveness.Medicina (Kaunas, Lithuania) · 2023Article
- The Association of Polymorphisms in Genes Encoding Antioxidant Enzymes GPX1 (rs1050450), SOD2 (rs4880) and Transcriptional Factor Nrf2 (rs6721961) with the Risk and Development of Prostate Cancer.Medicina (Kaunas, Lithuania) · 2022Article
- Review
- Article
- An Assessment ofGenes · 2022Article
- The Association of Polymorphisms inOxidative medicine and cellular longevity · 2021Article
- The Role of GPX1 (rs1050450) Variants in Ovarian Cancer Susceptibility Within a Turkish Population.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glutathione peroxidase (GPX), one of the antioxidant enzymes, exerts a vital role in reducing oxidative damage. GPX1 Pro198Leu (rs1050450) polymorphism has been reported in the development of several cancers, while the results were inconsistent. We thus conducted this meta-analysis to identify the association between GPX1 (rs1050450) polymorphism and cancer risk. 52 eligible publications with 60 case-control studies were included, with 21,296 cancer patients and 30,346 controls. The results in total population suggested there was a significant association between GPX1 (rs1050450) polymorphism and cancer susceptibility in part genetic models (TT vs CT+CC: OR = 1.15, 95% CI = 1.01-1.32, P = 0.042; TT vs CC: OR = 1.15, 95% CI = 1.00-1.31, P = 0.044; T vs C: OR = 1.09, 95% CI = 1.01-1.17, P = 0.02). The stratified analysis by cancer types suggested a positive correlation between GPX1 (rs1050450) polymorphism and the development of bladder cancer (TT+CT vs CC: OR = 1.72, 95% CI = 1.09-2.70, P = 0.019; TT vs CT+CC: OR = 3.56, 95% CI = 1.42-8.94, P = 0.007; TT vs CC: OR = 3.75, 95% CI = 1.41-9.94, P = 0.008; T vs C: OR = 1.941, 95% CI = 1.17-3.22, P = 0.01) as well as head and neck cancer (TT vs CT+CC: OR = 2.19, 95% CI = 1.39-3.46, P = 0.001) and brain cancer (TT+CT vs CC: OR = 1.19, 95% CI = 1.03-1.37, P = 0.018). These results support that GPX1 (rs1050450) polymorphism might be a candidate marker for cancer risk with type-specific effects.
Indexed as
Identifiers
31966829PMC6965984What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.